Lead poisoning is known to cause myelin defects. Galactolipids are the major lipid components of myelin and myelin-competent oligodendrocytes. The present study examines the cellular activity of enzymes involved in the galactolipid pathway, tissue concentrations of galactolipids, and the cellular activity of 2,3-cyclic nucleotide 3-phosphohydrolase (CNPase) in rat pups exposed to lead in utero and subsequently through maternal milk from exposed mothers and in drinking water following weaning. Pups from control and lead-treated groups (500 or 2000 ppm lead in the drinking water) were euthanized by decapitation on postnatal day 7, 14, 21, 35, or 56. Lead decreased levels of galactolipids and the oligodendrocyte marker CNPase in the brain to a similar degree. The ratios of galactocerebrosides/sulfatides and nonhydroxy fatty acid/hydroxy fatty acid forms of the galactolipids were not altered by lead treatment. In contrast, the activities of the galactolipid metabolic enzymes were reduced to a degree significantly greater than that of CNPase or galactolipids. These results are consistent with previously obtained data indicating that in vitro cultured oligodendroglial progenitor cells are a target for Pb toxicity. Chronic Pb exposure may impact on brain development by impairing timely myelin production due to perturbation of the early developmental commitment of oligodendroglial progenitors. It is further suggested that perturbation of the galactolipid pathway during the developmental maturation of oligodendrocytes may represent a contributing mechanism for Pb-induced neurotoxicity.
Lead poisoning is presently the most common disease of environmental origin in the United States (Goyer, 1993; Banks et al., 1997) . Pediatric populations are especially vulnerable because of a greater relative exposure to Pb and an increased sensitivity of the developing nervous system (Landrigan and Todd, 1994; Cory-Slechta, 1995) . Although numerous studies suggest that multiple molecular targets exist for Pb toxicity, including ion channels, neurotransmitters, signaling molecules, and metal-binding proteins (see Banks et al., 1997) , current data are still more suggestive than conclusive. While the primary mechanism(s) by which Pb causes the untoward effects on the brain remains largely unclear, identification of pathways affected by the metal is crucial for appreciating the risks associated with Pb exposure and the development of preventive and therapeutic strategies for dealing with Pb toxicity.
Pb is known to cause hypomyelination (Krigman et al., 1974; Tennekoon et al., 1979; Toews et al., 1980; Morell, 1984; Duncan, 1985; Goyer, 1993; Banks et al., 1997) . Myelin is a critical element for efficient pulse transmission of signals in the nervous system and alteration in myelination may well contribute to Pb-induced neurotoxicity. In vitro experiments have revealed that the myelin competent oligodendrocyte is the most Pb-sensitive cell type in the brain (Tiffany-Castaglioni et al., 1989) . Nevertheless, the mechanism by which Pb causes myelin deficits is unclear. Previously, we have shown that Pb treatment of fibroblasts from individuals who have pseudodeficiency polymorphisms of the arylsulfatase A (ARSA) 2 gene causes levels of this enzyme to fall below the critical threshold for normal galactolipid metabolism (Poretz et al., 2000) . It is known that inadequate levels of ARSA result in the accumulation of the galactolipid sulfatide and culminate in the inherited demyelinating disease metachromatic leukodystrophy (MLD, Kolodny and Fluharty, 1995; Kihara et al., 1982) . Mutations of the ARSA gene that cause MLD result in residual enzyme levels of 0 -10% of normal levels (Kolodny and Fluharty, 1995; Conzelmann and Sandhoff, 1991) . Polymorphisms of the gene causing pseudodeficiency of ARSA give rise to approximately 20 -30% residual levels of the enzyme. This pseudodeficiency condition, however, appears to be benign (Gieselmann et al., 1989; Barth et al., 1994) . We have proposed that a contributing mechanism for Pb-induced neurotoxicity is that critically low levels of ARSA are induced in children possessing pseudodeficiency polymorphisms at sensi-tive stages of nervous system development (Poretz et al., 2000) . While it is established that galactolipids, galactocerebrosides and sulfatides, are major lipid components characteristic of myelin, little is known about the impact of Pb exposure on galactolipid metabolism in vivo. In the present study, we report the effect of chronic dietary Pb exposure on the cellular activity of the anabolic and catabolic enzymes of the galactolipid pathway, tissue concentrations of galactocerebrosides and sulfatides, as well as the activity of CNPase in the developing rat brain.
MATERIALS AND METHODS
Lead exposure. Pregnant Long-Evans rats were given water containing 0, 500, or 2000 ppm Pb as Pb acetate starting at 1 week of gestation and were maintained on Purina Purified Basal Diet as described by Widzowski and Cory-Slechta (1994) . Following birth, the pups received milk from the continuously exposed mothers and Pb-containing drinking water after weaning. Animals were maintained at 23°C on a 12/12-h light-dark cycle with free access to rat chow and either deionized water or the same water containing 500 or 2000 ppm Pb. Five pups from the control group and each Pb-treated group were euthanized by decapitation on postnatal day (PND) 7, 14, 21, 35, and 56. Each group was composed of animals from three randomized litters, except when one or two litters were each employed once. Brains were removed rapidly, weighed, and stored at Ϫ80°C. Blood was obtained by exsanguination of the decapitated pup for Pb analysis performed by the Bureau of Biological Research of Rutgers University employing atomic absorbance spectroscopy analysis (Burger et al., 1997) . The protocol employed for these animal studies was approved by Rutgers University Animal Care and Facilities Committee.
Tissue homogenate preparation and protein determination. Tissue homogenates (20% w/v) were made in 10 mM Tris-HCl buffer (pH 7.4) using a PowerGen 700 homogenizer (Fisher Scientific) on ice for 3 ϫ 10 s, and stored at Ϫ80°C. An aliquot of the homogenates was boiled at 100°C for 30 min and used as the blank control in enzyme assays described below. Protein content of samples was determined by the method of Lowry et al. (1951) . van der Pal et al. (1990) . The reaction was initiated by the addition of 0.1 ml 2.5% (w/v) brain homogenate to 0.1 ml of the assay mix. The product, separated in the organic phase, was counted by liquid scintillation. The specific enzyme activity was calculated as pmol/h [ 35 S]sulfatides formed per mg protein.
3-Phosphoadenosine
UDP-galactose:ceramide galactosyltransferase (CGalT, EC 2.4.1.45) assay. CGalT activity was determined by measuring the radioactive galactocerebrosides formed by the enzymic transfer of [ 14 C]galactose from UDP-[U-14 C]galactose to ceramides, as described by Neskovic et al. (1981) . For accurate and reproducible measurements, the lipid substrates were prepared in individual assay tubes. Eight microliters of 2.5% tissue homogenate was employed as the enzyme source. The product, isolated in the organic phase, was counted by liquid scintillation. The specific enzyme activity was calculated as pmol/h of [ 14 C]galactocerebrosides formed per mg protein.
Arylsufatase A (EC 3.1.6.1) assay. ARSA was measured as described by Baum et al. (1959) using p-nitrocatechol sulfate (pNCS) as the substrate. The synthetic substrate, pNCS, can be hydrolyzed by non-ARSA sulfatases which are expressed abundantly in rat brain. The widely accepted method for analysis of ARSA in human tissues (Lee-Vaupel and Conzelmann, 1987) was found to give high values due to the presence of high levels of non-ARSA sulfatases in the rat brain preparations (data not shown). To remove interfering non-ARSA sulfatases, the enzyme source was partially purified using anion exchange adsorption by a modification of the approach reported by van der Pal et al. (1991) . The anion exchange resin was applied as a suspension into a small spin column (Bio-Rad) to enable the quick and efficient analysis of a number of samples. The assay was performed as follows: brain homogenate was frozen and thawed twice, diluted to 5% (w/v) with 20 mM Tris-maleate buffer (pH 8.0), and centrifuged at 350,000g for 10 min at 4°C. The supernatant was dialyzed against 20 mM Tris-maleate buffer (pH 8.0) overnight at 4°C. The dialysate (200 l) was diluted with the same buffer to 600 l and loaded onto a spin column (Bio-Rad) containing 500 l of packed DEAE Sephadex-A25 (Sigma). The suspension was mixed by periodic inversions of the column for 15 min and the nonabsorbed fraction (non-ARSA proteins) was collected by centrifugation at 1,000g for 2 min at 4°C. The resin was washed twice with 600 l 20 mM Tris-maleate buffer (pH 8.0). ARSA was eluted with 600 l 40 mM Tris-HCl buffer (pH 6.0) containing 250 mM NaCl. For the enzyme assay, 300 l of the appropriate fraction was incubated for 10 min at 37°C with 100 l of an assay mix containing 80 mM pNCS and 1 M sodium acetate buffer (pH 5.6). The reaction was stopped with 0.5 ml 2 M NaOH and the optical density was measured at 515 nm (⑀ M ϭ 12,000/cm). A homogenate of the brain from an ARSA gene knockout mouse (gift from V. Gieselmann, University of Bonn, Germany) was prepared as described for the experimental rat brains and used as a control for a rodent brain lacking ARSA activity. It was found that clarified brain homogenates from normal rats yielded ARSA enzymic activity in the fraction bound to the DEAE Sephadex-A25 adsorbant and eluted with high ionic strength buffer. In contrast, brain homogenates from ARSA gene knockout mice gave no detectable ARSA activity, although normal levels of non-ARSA sulfatases were obtained in the DEAE Sephadex-A25 nonabsorbed fraction (data not shown). These results demonstrate the specificity of the assay for ARSA, even when the tissue being analyzed contains significant amounts of non-ARSA sulfatases. The absence of detectable pNCS desulfatase activity with this control preparation gave confidence that the assay was specific for ARSA.
Galactocerebroside-␤-galactosidase (galactocerebrosidase, GalCase, EC 3.2.1.46) assay. GalCase was measured by the method of Zeigler et al. (1984) , using a fluorogenic substrate 12-[N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)]aminododecanoylsphingosyl-␤-D-galactoside (NBD-galactocerebroside, Sigma). Brain homogenate (20% w/v) was centrifuged at 23,000g for 30 min at 4°C, and the supernatant (100 l) was used as the enzyme source. Fluorescence intensity of the recovered product was measured with a model LS 50B Perkin-Elmer Luminescence Spectrometer ( ex ϭ 452 nm, em ϭ 515 nm). NBD-ceramide (Matreya) dissolved in heptane was used to develop a standard curve.
2,3-Cyclic nucleotide 3-phosphohydrolase (CNPase, EC 3.1.4.37) assay. CNPase was determined in brain homogenate (20% w/v), diluted 100-fold with 0.2 M Tris-HCl buffer (pH 7.5) containing 1% Triton X-100 and 0.2% BSA, by the method described by Sogin (1976) . The NADPH formed was measured by the increase in absorbance at 340 nm (⑀ M ϭ 622,000/cm) with a PerkinElmer Lamda B spectrophotometer and associated computer software. Enzyme activity, as mol of NADPH reduced per min per mg of protein, was calculated from the change of absorbance.
HPLC analysis of brain galactolipids.
To quantify the tissue concentrations of galactolipids in the brain, HPLC analysis was carried out following lipid extraction, fractionation, desulfation, and benzoylation, by a slight modification of the method described by de Haas and Lopes-Cardozo (1995). Tissue was homogenized in 10 mM Tris-HCl buffer (pH 7.4) containing 0.74% KCl, extracted twice with 20 vol of C/M (2:1), and washed twice with 5 vol of C/M/0.74% aqueous KCl (3:48:47) . Total lipids in the organic phase were dried, redissolved in 0.2 ml C/M (2:1), diluted with 3.5 ml chloroform, and fractionated on a small prefilled silica (0.5 g) column (Fisher Scientific). Neutral lipids were eluted with 10 ml chloroform. The second fraction, which eluted with 15 ml acetone:methanol (9:1), contained the galactolipids, leaving the phospholipids bound to the silica. Subsequently, sulfated galactolipids were separated from neutral glycolipids by anion exchange chromatography on a 3-ml bed of DEAE-Sephadex-A25 (Sigma) packed with C/M/H 2 O (3:6:0.8) in a 10-ml glass pipette. Total galactolipids were dissolved with 1 ml C/M/H 2 O (3:6:0.8) and loaded onto the column. Galactocerebrosides were eluted with 15 ml of the same solvent followed by elution of sulfatides with 15 ml C/M/0.8 M aqueous ammonium acetate (3:6:0.8). The solvent was evaporated and residual ammonium acetate was removed by partition with 2 ml C/M/H 2 O (1:2:0.8), 2 ml chloroform, and 2 ml H 2 O. Lipids in the organic fraction were desulfated with 1.5 ml 50 mM methanolic HCl overnight at room temperature. Samples containing galactocerebrosides or desulfated sulfatides were dried in vacuo over P 2 O 5 . Perbenzoylation was performed by the addition of benzoylchloride (0.04 ml) and dry pyridine (0.16 ml). Tubes were capped and incubated for 1 h at 60°C. Following evaporation of the liquid under a steam of nitrogen, 1 ml methanol:1% aqueous Na 2 CO 3 (4:1) and 3 ml hexane were added, and the mixture was vortexed. The hexane phase was separated and washed with 1 ml methanol:1% aqueous Na 2 CO 3 (4:1), followed with 1 ml methanol:H 2 O (4:1), and used for HPLC analysis directly or after concentration of solutes, if necessary. HPLC was performed with a Waters-Millennium system using a silica column (Varian, 250 ϫ 4.6 mm, 5-m particle size, 100 Å pore size). The components of the applied sample were separated with an elution gradient of 0.5% isopropanol in hexane (solvent A) and 10% isopropanol in hexane (solvent B). A linear gradient of 100% A 3 83% A ϩ 17% B for 15 min at 1.5 ml/min was followed by 1 min of a linear gradient to 100% B and 4 min of an isocratic elution with B. Elutions of the perbenzoylated galactolipids were as monitored by absorbance at 230 nm and each was 
Statistical analysis.
Each HPLC analysis and enzyme assay included three or five animals, respectively. All of the assays were carried out in duplicate. Statistical comparisons on all experiments were performed by using analysis of variance between control and treatment groups, as well as using ANOVA intergroup comparisons. A p Ͻ 0.05 was used to determine statistical significance. Correlation analysis was performed between the developmental profiles of galactolipids and the myelin marker protein CNPase.
RESULTS
The pups in the Pb-treated litters exhibited decreased body weights compared to those in the control groups. As shown in Table 1 , the difference was significant for the animals at PND 14 and PND 7 in the 500-and 2000-ppm groups, respectively. By PND 21 (at termination of weaning), both groups of Pbtreated animals appeared to be approximately 20% lighter and, by PND 56 (3 weeks postweaning), approximately 25% smaller than the control group. This effect is consistent with the impact of Pb intoxication during development, as documented by others (Toews et al., 1980; Gong and Evans, 1997) . The values obtained for both Pb-exposed groups for PND 35 may be anomalous. The large value for the SEM obtained for the 500-ppm Pb-exposed group appears to be due to the inclusion of animals from two litters. All the animals from a large litter of seven pups were similar, but 29% lighter, than those of the other litter of three pups. The pups from the 2000-ppm Pb-treated group at PND 35 were from the same litter of six pups and may well represent members of a relatively undernourished large litter. In contrast to the pups, the body weights of the Pb-treated dams at postpartum day 56 showed no significant difference from those of the dams in the control group.
Determination of whole blood Pb levels from animals euthanized for evaluation of brain biochemical parameters showed that the pups possessed relatively high concentrations of Pb during the weaning period and this value rose dramatically in PND 35 and 56 (Table 1 ). The mothers, at postpartum day 56, exhibited blood Pb levels generally higher than those of the weaning pups but less than those observed for the pups at PND 56.
Lead exposure causes a loss of total brain CNPase activity.
The specific activity of CNPase, an enzyme indicative of myelinating oligodendrocytes, in the developing brains of control and Pb-exposed rats is shown in Fig. 1 . The cellular enzyme activity was age dependent, consistent with observed developmental profiles for the rat (Bansal and Pfeiffer, 1985) and murine brain (Kurihara et al., 1970) . Pb treatment in both the 500-and 2000-ppm groups caused a decrease on CNPase activity (Fig. 1 ). An 11-27% reduction of the specific enzyme activity was observed depending upon the developmental stage of the animals and dose of Pb exposure.
Lead exposure reduces the amount of galactolipid biosynthetic enzymes in the brain. The developmental profiles of CGalT and GalCST for control animals, as shown in Fig. 2 , are consistent with those described by van der Pal et al. (1990) . Peak activities of both enzymes were observed at 3 weeks of development in the rat brain. Pb-exposed animals exhibited a decrease in both CGalT and GalCST activities compared to the control animals. The maximum relative reduction of specific enzyme activities in rats exposed to Pb was found at the peak time of development (Fig. 2) . The effect was more pronounced with rats in the 2000-ppm group than with those on the 500-ppm regimen. The higher dose caused an approximately 30% decrease in GalCST activity at PND 21, and CGalT activity was reduced by as much as 49%.
Lead exposure decreases the amount of ARSA and GalCase activity in total brain homogenates. Utilizing the pNCS assay with partially purified brain extracts, we observed a developmental profile of ARSA in control rats similar to that previously reported for cerebroside sulfatase (EC 3.1.6.8, van der Pal et al., 1991) . GalCase and ARSA activity profiles in the developing brains of control and Pb-exposed rats are shown in Fig. 3 . Pb had a significant effect on the enzymes responsible for degradation of galactolipids throughout the development of the animals. Pb exposure to 500 and 2000 ppm Pb resulted in a 28 -49% reduction in GalCase and a 13-33% decrease in ARSA activities, respectively ( p Ͻ 0.01 vs control for each).
Lead exposure decreases the level of all galactolipid species without altering the relative proportion of each.
To determine the outcome on glycolipid levels of the Pb-related decrease in galactolipid metabolic enzymes, both nonhydroxy fatty acid (NFA) and hydroxy fatty acid (HFA) species of galactolipids were quantified. This was accomplished by HPLC employing radioactive internal standards following lipid extraction, fractionation, desulfation, and benzoylation. A typical chromatogram of galactolipids obtained from rat brains is shown in Fig. 4 . The multiple peaks representing the NFA and HFA fractions of galactolipids reflect the heterogeneity of each of these fractions caused by the presence of different fatty acid chain derivatives for each family of glycolipid. The developmental profiles for the different types and forms of galactolipids in the control rats are similar to those reported by de Haas and Lopes-Cardozo (1995) . The galactolipid levels as the sum of NFA and HFA species are shown in Fig. 5 . At PND 7, both the galactocerebrosides and sulfatides were composed almost exclusively by the NFA species. As shown in Fig. 6 , at 2 weeks of postnatal development, the NFA species represented 78% of galactocerebrosides and 94% of sulfatides. The proportion of NFA, however, dropped sharply in subsequent weeks for both galactolipids. The ratio of NFA/HFA galactocerebrosides was less than 1, but the ratio of NFA/HFA sulfatides remained greater than 1 (Fig. 6) , indicating that HFA species were relatively enriched in galactocerebrosides compared to sulfatides in the myelinated rat brain. Exposure of rats to Pb (500 and 2000 ppm) caused a significant loss of the various forms of galactolipids in the brain compared to the control groups (Fig.  5) . Nevertheless, the ratio of NFA/HFA species for both galactolipids was not altered by Pb treatments for either the 500-or the 2000-ppm group nor was there a significant consequence of Pb on the ratio of galactocerebrosides/sulfatides (Fig. 6) .
The decrease in galactolipid content parallels the loss of myelin-competent cells, but cellular activities of the galactolipid metabolic enzymes are reduced to a greater degree. It has been noted that CNPase, sulfatides, and galactocerebrosides are markers for myelin-competent oligodendrocytes (Pfeiffer et al., 1993) . As expected, the developmental profile of each galactolipid correlated with that of CNPase ( p Ͻ 0.05, galactocerebrosides vs CNPase: n ϭ 5, r 2 ϭ 0.862; sulfatides vs CNPase: n ϭ 5, r 2 ϭ 0.835). The reduction of CNPase in Pb-exposed animals is consistent with a Pb-induced decrease of myelination (see above and Tennekoon et al., 1979; Morell, 1984; Goyer, 1993) . The brain galactolipid biosynthetic enzymes, CGalT and GalCST, are expressed primarily in oligodendroglial cells, and the catabolic enzymes, ARSA and GalCase, are expressed ubiquitously (Ishizuka, 1997) . Accordingly, evaluation of the impact of Pb on each of the biosynthetic enzymes and galactolipids in total brain homogenates, independent of oligodendrocyte loss, can be determined by comparing the relative reduction of each enzyme and galactolipid with regard to changes in total brain CNPase at the same developmental stage. Changes in levels of ARSA and GalCase, however, need to be compared to total protein in brain homogenates. There is a 10 -20% greater decrease in the cellular activity of CGalT than that of CNPase in both 500-and 2000-ppm Pb-treated groups when the percent decrease relative to control for each biosynthetic enzyme is compared with that of CNPase (Fig. 7) . The level of GalCST also is decreased to an extent grater than that of CNPase at PND 21 during the peak developmental period ( p Ͻ 0.05, Fig. 7) . Clearly, Pb has a considerable impact upon the concentrations or activities of the galactolipid metabolic enzymes. Nevertheless, levels of both oligodendrocyte-related galactolipids paralleled the Pbinduced reduction of CNPase (Fig. 7) .
DISCUSSION
Pb intoxication affects numerous organs (Goyer, 1993; Banks et al., 1997) and may cause significant neurobehavioral deficits in humans exposed to relatively low levels for a prolonged period of time (Cory-Slechta, 1995; Bellinger and Needleman, 1992) . At considerably higher doses, Pb causes hypomyelination (Krigman et al., 1974; Tennekoon et al., FIG. 4 . A representative HPLC chromatogram demonstrating the resolution of the NFA and HFA species of galactocerebrosides from total brain homogenate of a 5-week-old control rat. The multiple peaks representing the NFA and HFA fractions reflect the heterogeneity of each of these fractions due to the presence of different fatty acid chain derivatives.
1979; Toews et al., 1980; Duncan, 1985; Goyer, 1993) . Widzowski and Cory-Slechta (1994) exposed weaning rat pups to Pb from PND 1 by incorporating Pb salts into the drinking water of the mothers and observed significant accumulation in all regions of the brain. Application of a Pb treatment protocol utilizing drinking water containing 750 ppm Pb, although otherwise similar to that employed for the present research, resulted in offspring that appeared to have affected protein kinase C activity in the developing rat brain (Reinholz et al., 1999) . The protocol used in our studies is similar to that published by Widzowski and Cory-Slechta et al. (1994) who examined the effect of up to 2000 ppm lead acetate in the drinking water of nursing mothers on postnatal rat pup brain lead concentrations. We, however, detected somewhat higher blood Pb levels than they, throughout the 21-postnatal-day period of the exposure. The blood Pb levels of approximately 60 g/dL we observed in rat pups at PND 7 and 14 in the 500-ppm experimental group are high compared to those seen in most children presenting with elevated Pb in the United States but are within the range found with some children chronically exposed to environmental Pb (Matyas et al., 1995; Shen et al., 1996) . The 500-ppm regimen employed in the studies reported here resulted in a Pb-induced decrease by PND 35 of up to 21% of the myelin specific enzyme CNPase. This is consistent with a significant reduction of brain myelination demonstrated earlier in rodents (Krigman et al., 1974; Tennekoon et al., 1979; Toews et al., 1980) . These researchers found that Pb caused a significant reduction of the two characteristic proteins of compact myelin, myelin basic protein and proteolipid protein, as well as total myelin mass. Tennekoon et al. (1979) found that, when litter size was reduced to three pups, Pb-treated and control mice had similar body and brain weights from PND 7 to 42, presumably due to reduced competition for mother's milk. Nevertheless, the CNPase and GalCST activity profiles, markers employed by them to follow optic nerve myelination, were virtually identical to the patterns observed by us during brain development in control and Pb-exposed rat pups. These results further support the contention that changes in galactolipid and related enzyme activity levels studied here are due to Pb, independent of potential undernutrition effects caused by Pb.
The insulating property of myelin is due largely to its high lipid content (70% of dry myelin weight). Myelin resembles other cellular membranes in phospholipid and cholesterol content, but differs in that it contains an abundance of galactocerebrosides and sulfatides (Coetzee et al., 1998; Pfeiffer et al., 1993; Vos et al., 1994) . We found that Pb exposure caused a significant decrease in levels of myelin-specific galactolipids, galactocerebrosides and sulfatides in rat brain. These galactolipids are present in the membranes of myelin-competent oligodendrocytes and compact myelin. Since the reduction of both galactolipids paralleled that of CNPase, a protein enriched in myelin-competent oligodendrocytes and uncompacted myelin but absent in compacted myelin, it appears that this decrease is due to loss of myelin-competent and compact myelinforming oligodendrocytes. There appears to be no significant consequence of Pb exposure on galactolipid levels in the residual mature oligodendrocytes. This is further highlighted by the observation that the ratios of galactocerebrosides/sulfatides and the NFA/HFA forms of each type of the galactolipid are not altered in the brains of Pb-exposed animals compared to controls. Interestingly, we found that 1 M Pb exposure was cytotoxic to oligodendroglial progenitor (OP) cells when cultured under conditions encouraging proliferation, but delayed the development of these cells into myelin-forming oligodendrocytes and caused a decrease in the biosynthesis of galactolipids when they were cultured under conditions for differentiation (Deng et al., 2001) . We also observed that OPs are considerably more sensitive than mature myelin-competent oligodendrocytes to the effects of Pb. Accordingly, OPs may represent a target for Pb toxicity in vivo, leading to their loss and/or the reduced ability of these cells to respond to differentiation signals. Chronic Pb exposure may thus impact on brain development by impairing timely myelin production due to perturbation of the early developmental commitment of OPs.
Oligodendroglial galactolipids appear to be involved in developmental signal transduction and influence protein trafficking and membrane stability (Coetzee et al., 1998) . Mice lacking the ability to synthesize galactolipids form dysfunctional and unstable myelin (Coetzee et al., 1996; Bosio et al., 1996) . An inadequate amount of ARSA results in the accumulation of sulfatide and causes MLD, and the deficiency of GalCase leads to Krabbe disease in humans (Wenger and Louie, 1991) . These findings suggest that appropriate levels of galactolipids are essential for myelin development and structure. Perturbation of the necessary levels of galactolipids during the developmental maturation of oligodendrocytes may represent a contributing mechanism for Pb-induced neurotoxicity. The amounts of sulfatides and galactocerebrosides present at any moment are the consequence of the relative rates of synthesis and catabolism for these galactolipids. While the catabolic enzymes are present in all types of brain cells, the transferases are found almost exclusively, or greatly enriched, in oligodendrocytes (Ishizuka, 1997; Pfeiffer et al., 1993) . The effect of Pb on the
FIG. 6.
Relationship between NFA and HFA galactolipids (A, galactocerebrosides; B, sulfatides) and between galactocerebrosides and sulfatides (C) in control and lead-treated rat brains. The data represent means Ϯ SEM (n ϭ 3, each in duplicate). No significant change between control and lead-treated rats was detected.
galactolipid biosynthetic enzymes GalCST and CGalT in myelin-capable oligodendroglial cells is more pronounced than that observed for CNPase, especially during the peak time of myelination, suggesting that Pb alters levels of cellular activity of these enzymes. The Pb exposure regimen, however, caused a profound decrease in activities of total brain GalCase and ARSA, the catabolic enzymes that are present in all cell types. Nevertheless, the Pb-induced (2000 ppm Pb) decrease of up to 49 and 33% in GalCase and ARSA activity, respectively, may not be to the degree expected to alter galactolipid catabolism in normal rat brain. In humans, and presumably in rodents, the cellular activities of these lysosomal enzymes are present in several fold excess needed for normal metabolism (Leinekugel et al., 1992; Conzelmann and Sandhoff, 1983) . We had previously shown that Pb can induce critically low levels of ARSA in fibroblasts from individuals with pseudodeficiency polymorphisms of the ARSA gene, but not in fibroblasts from people with the normal alleles (Poretz et al., 2000) . The combined effects of Pb and these genetic factors to cause abnormal galactolipid metabolism may augment other deleterious consequences of Pb on the survival and developmental maturation of oligodendrocyte progenitors. Accordingly, children homozygous for ARSA pseudodeficiency polymorphisms may exhibit greater Pb-induced neurological/behavioral deficits than children possessing normal ARSA alleles.
